Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction ≤ 30%
European Journal of Heart Failure, Volume 8, No. 3, Year 2006
Notification
URL copied to clipboard!
Description
Aims: Because of the prognostic importance of LV dysfunction following an AMI and the increasing use of electrical and/or mechanical interventions in patients with LV systolic dysfunction, this retrospective analysis of EPHESUS patients with LVEF ≤ 30% at baseline was conducted to determine the value of eplerenone in this setting. Methods and results: In EPHESUS, 6632 patients with LVEF ≤ 40% and clinical heart failure (HF) post-AMI who were receiving standard therapy were randomized to eplerenone 25 mg/day titrated to 50 mg/day or placebo for a mean follow-up of 16 months. Treatment with eplerenone in the subgroup of patients with LVEF ≤ 30% (N = 2106) resulted in relative risk reductions of 21% versus placebo in both all-cause mortality (P = 0.012) and cardiovascular (CV) mortality/CV hospitalization (P = 0.001), and 23% for CV mortality (P = 0.008). The relative risk of sudden cardiac death (SCD) was reduced 33% (P = 0.01) and HF mortality/HF hospitalization was reduced 25% (P = 0.005) with eplerenone compared with placebo. Within 30 days of randomization, eplerenone resulted in relative risk reductions of 43% for all-cause mortality (P = 0.002), 29% for CV mortality/CV hospitalization (P = 0.006), and 58% for SCD (P = 0.008). Conclusions: Treatment with eplerenone plus standard therapy in patients with post-AMI HF and LVEF ≤ 30% provided significant incremental benefits in reducing both early and late mortality and morbidity. © 2005 European Society of Cardiology.
Authors & Co-Authors
Pitt, Bertram
United States, Ann Arbor
A. Alfred Taubman Health Care Center
Gheorghiade, Mihai
United States, Chicago
Northwestern University Feinberg School of Medicine
Zannad, Faïez Mohamed
France, Dommartin-les-toul
Hopital Jeanne D'arc
Anderson, Jeffrey L.
United States, Salt Lake City
Lds Hospital
van Veldhuisen, Dirk Jan
Netherlands, Groningen
Universitair Medisch Centrum Groningen
Parkhomenko, Alexander N.
Ukraine, Kyiv
National Scientific Center M.d. Strazhesko Institute of Cardiology
Corbalàn, Ramõn L.
Chile, Santiago
Pontificia Universidad Católica de Chile
Klug, Eric Q.
South Africa, Sandton
Sunninghill Hospital
Mukherjee, Robin
United States, New York
Pfizer Inc.
Solomon, Henry
United States, New York
Pfizer Inc.
Statistics
Citations: 10
Authors: 10
Affiliations: 9
Identifiers
Doi:
10.1016/j.ejheart.2005.11.008
ISSN:
13889842
Research Areas
Noncommunicable Diseases
Study Design
Randomised Control Trial
Cohort Study